The healthcare industry utilizes many acronyms and similar sounding terms that can often be misinterpreted. The same is certainly true within pharmacy benefit programs. Today, we’re going to look at multi-indication brands and multi-source brands to help clarify the differences.

What are Multi-Indication Brands?

Multi-indication brands are drugs that have more than one use approved by the FDA. For example, the drug Lisinopril. Lisinopril is one of the most common drugs dispensed in the US and can be administered for multiple treatments and preventative measures. This drug can be prescribed for hypertension, heart failure with reduced ejection fraction, and ST-elevation myocardial infarction (a blockage in one or more coronary arteries).

What are Multi-Source Brands?

Multi-source brands are drugs that are made by more than one drug manufacturer, and it does not have any generics available. These drugs are normally co-licensed brands. Multi-source brands are part of the MONY code which was created by Medi-Span® to differentiate drug product status. An example of a multi-source brand would be Lantus. Lantus is an insulin drug prescribed to treat diabetes.

If you’re in need of better understanding of other pharmacy related terms or acronyms, more information can be found within our MONY code page. If you have any other additional questions, please reach out to PillarRx here.